QURE – uniQure N.V.
uniQure N.V.QURE
$26.46Name : uniQure N.V.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,668,765,568.00
EPSttm : -3.42
uniQure N.V.
$26.46
2.00%$0.54
QURE — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
18.2
Margin Of Safety %
Put/Call OI Ratio
0.18
EPS Next Q Diff
0.1
EPS Last/This Y
0.47
EPS This/Next Y
0.56
Price
26.5
Target Price
38.33
Analyst Recom
1.57
Performance Q
44.91
Upside
-391.8%
Beta
1.02
Ticker: QURE
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-05-11 | QURE | 27.66 | 0.18 | 0.12 | 137811 |
| 2026-05-12 | QURE | 29.11 | 0.18 | 0.13 | 139039 |
| 2026-05-13 | QURE | 29.15 | 0.19 | 0.10 | 144217 |
| 2026-05-14 | QURE | 27.8 | 0.19 | 0.18 | 147064 |
| 2026-05-15 | QURE | 27.05 | 0.19 | 0.37 | 148918 |
| 2026-05-18 | QURE | 24.91 | 0.17 | 0.14 | 110484 |
| 2026-05-19 | QURE | 24.71 | 0.16 | 0.24 | 115969 |
| 2026-05-20 | QURE | 24.59 | 0.16 | 0.37 | 117072 |
| 2026-05-21 | QURE | 24.8 | 0.17 | 0.74 | 117414 |
| 2026-05-22 | QURE | 24.15 | 0.17 | 0.37 | 117986 |
| 2026-05-26 | QURE | 25.18 | 0.17 | 0.18 | 118644 |
| 2026-05-27 | QURE | 25.14 | 0.17 | 0.70 | 119547 |
| 2026-05-28 | QURE | 24.82 | 0.17 | 0.98 | 120177 |
| 2026-05-29 | QURE | 28.49 | 0.17 | 0.11 | 120640 |
| 2026-06-02 | QURE | 26.78 | 0.18 | 0.06 | 127088 |
| 2026-06-03 | QURE | 29.86 | 0.18 | 0.13 | 125981 |
| 2026-06-04 | QURE | 27.98 | 0.17 | 0.19 | 134797 |
| 2026-06-05 | QURE | 26.46 | 0.18 | 0.11 | 141242 |
| 2026-06-08 | QURE | 27.03 | 0.18 | 0.11 | 143225 |
| 2026-06-09 | QURE | 26.49 | 0.18 | 0.26 | 144092 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-05-11 | QURE | 27.66 | -19.7 | - | -3.02 |
| 2026-05-12 | QURE | 29.12 | -19.0 | - | -3.01 |
| 2026-05-13 | QURE | 29.15 | -20.7 | - | -3.01 |
| 2026-05-14 | QURE | 27.76 | -20.7 | - | -2.98 |
| 2026-05-15 | QURE | 27.03 | -19.9 | - | -2.99 |
| 2026-05-18 | QURE | 24.90 | -19.9 | - | -2.99 |
| 2026-05-19 | QURE | 24.69 | -19.9 | - | -2.99 |
| 2026-05-20 | QURE | 24.58 | -19.9 | - | -2.99 |
| 2026-05-21 | QURE | 24.78 | -19.9 | - | -2.99 |
| 2026-05-22 | QURE | 24.19 | -19.9 | - | -2.99 |
| 2026-05-26 | QURE | 25.15 | -19.9 | - | -2.99 |
| 2026-05-27 | QURE | 25.15 | -19.9 | - | -2.99 |
| 2026-05-28 | QURE | 24.85 | -19.9 | - | -2.99 |
| 2026-05-29 | QURE | 28.55 | -19.9 | - | -2.99 |
| 2026-06-01 | QURE | 28.22 | -19.9 | - | -2.99 |
| 2026-06-02 | QURE | 26.78 | -19.9 | - | -2.99 |
| 2026-06-03 | QURE | 29.91 | -19.9 | - | -2.99 |
| 2026-06-04 | QURE | 27.99 | -19.9 | - | -2.99 |
| 2026-06-05 | QURE | 26.54 | -19.9 | - | -2.99 |
| 2026-06-08 | QURE | 27.02 | -19.9 | - | -2.99 |
| 2026-06-09 | QURE | 26.50 | -19.9 | - | -2.99 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-05-11 | QURE | -3.36 | 0.37 | 19.26 |
| 2026-05-12 | QURE | -3.31 | 0.37 | 18.72 |
| 2026-05-13 | QURE | -4.34 | 0.37 | 18.44 |
| 2026-05-14 | QURE | -4.34 | 0.37 | 18.44 |
| 2026-05-15 | QURE | -4.34 | 0.37 | 18.44 |
| 2026-05-18 | QURE | -4.34 | -4.58 | 18.76 |
| 2026-05-19 | QURE | -3.52 | -4.58 | 18.76 |
| 2026-05-20 | QURE | -3.52 | -4.58 | 18.76 |
| 2026-05-21 | QURE | -3.52 | -4.58 | 18.76 |
| 2026-05-22 | QURE | -3.52 | -4.58 | 19.26 |
| 2026-05-26 | QURE | -2.73 | -5.67 | 19.26 |
| 2026-05-27 | QURE | -2.73 | -5.67 | 19.26 |
| 2026-05-28 | QURE | -2.73 | -5.67 | 18.39 |
| 2026-05-29 | QURE | -2.73 | -5.67 | 18.20 |
| 2026-06-02 | QURE | -2.99 | -6.23 | 18.20 |
| 2026-06-03 | QURE | -2.99 | -6.23 | 18.20 |
| 2026-06-04 | QURE | -2.99 | -6.23 | 18.20 |
| 2026-06-05 | QURE | -2.99 | -6.23 | 18.20 |
| 2026-06-08 | QURE | -3.03 | -6.29 | 18.20 |
| 2026-06-09 | QURE | -3.03 | -6.29 | 18.20 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.85
Avg. EPS Est. Current Quarter
-0.72
Avg. EPS Est. Next Quarter
-0.75
Insider Transactions
-3.03
Institutional Transactions
-6.29
Beta
1.02
Average Sales Estimate Current Quarter
4
Average Sales Estimate Next Quarter
Fair Value
Quality Score
41
Growth Score
27
Sentiment Score
8
Actual DrawDown %
62.9
Max Drawdown 5-Year %
-90.1
Target Price
38.33
P/E
Forward P/E
PEG
P/S
91.46
P/B
11.17
P/Free Cash Flow
EPS
-3.51
Average EPS Est. Cur. Y
-2.99
EPS Next Y. (Est.)
-2.44
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-1154.42
Relative Volume
0.56
Return on Equity vs Sector %
-100
Return on Equity vs Industry %
-100
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.02
EBIT Estimation
◆
QURE
Healthcare
$26.46
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
54.3
Range 1M
37.6%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-1.4%
EPS NY
13.2%
52W%
28.5%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+44.9% upside
Upside
+44.9%
Quality
41
uniQure N.V.Sector: Healthcare
Industry: Biotechnology
Employees: 221
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
QURE
Latest News
—
Caricamento notizie per QURE…
stock quote shares QURE – uniQure N.V. Stock Price stock today
news today QURE – uniQure N.V. stock forecast ,stock prediction 2023 2024 2025
marketwatch QURE – uniQure N.V. yahoo finance google finance
stock history QURE – uniQure N.V. invest stock market
stock prices QURE premarket after hours
ticker QURE fair value insiders trading